Tag Archives: Jan-Eric Ahlfors

Fortuna Fix Announces Series B Financing, Adding Amgen Ventures and Macnguyen Family Office as Shareholders

Posted on November 8, 2017 by

(Newswire.com) Press Release: November 8, 2017 Fortuna Fix – Fortuna Fix (“Fortuna”), a private, clinical-stage Regenerative Medicine company is aiming to be the first to bring to the clinic a patient’s own neural stem cells (autologous) produced by direct reprogramming … Continue reading →

Posted in Biomaterials, Chronic Spinal Cord Injury Research, Regenerative Medicine, Spinal Research, Stem Cell Research | Tagged ,

Breakthrough Regenerative Therapeutics Company Establishes Scientific Advisory Board

Posted on May 4, 2017 by

Montreal, Canada, May 4, 2017 (Newswire.com) – Fortuna Fix Inc. (“Fortuna”), a private, clinical-stage biotech company, is aiming to be the first to eliminate the need for embryonic and fetal stem cells by using direct reprogramming of autologous cells to treat … Continue reading →

Posted in Biomaterials, Chronic Spinal Cord Injury Research, Regenerative Medicine, Rehabilitation, Spinal Research, Stem Cell Research, Unite 2 Fight Paralysis | Tagged , , , , | 1 Comment

New World Laboratories pushes forward with clinical trial

Posted on January 23, 2015 by

New World Laboratories acts as its own research center, allowing it to create its own therapeutic platforms. The company focuses its efforts on three main sectors—therapeutic drugs, medical devices, and cell therapies. For example, the apoptosis program (programmed cell death) … Continue reading →

Posted in Biomaterials, Chronic Spinal Cord Injury Research, Regenerative Medicine, Spinal Research, Stem Cell Research | Tagged , , ,